Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 (Patentes Nacionales, Patentes Europeas, Informes Tecnológicos de Patentes y Búsquedas Retrospectivas) está cerrado desde el pasado 19 de junio. Se informará más adelante sobre su reapertura.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
129
resultados
Última actualización
07/07/2025 [14:45:00]
Resultados 50 a 75 de 129
Resumen de: WO2025075714A1
Described herein is a method of diagnosing and/or treating irritable bowel syndrome (IBS) in a subject. The method comprises determining a fatty acid profile in a stool sample of the subject; and comparing the fatty acid profile with a first reference profile indicating an absence of IBS or a second reference profile indicating IBS. Also described herein is a composition for treating IBS, which comprises two or more of a Monoglobaceae bacterium, a Lachnospiraceae bacterium; and a Ruminococcaceae bacterium, as well as a method of treating IBS using the same.
Resumen de: WO2025076081A1
The disclosure herein relates to the development and production of novel antibodies and antigen binding fragments thereof that bind TL1 A and that are useful in the treatment, prevention and diagnosis of a disease, disorder or inflammation including, for example, autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of final antibody structure being designed de novo by a computer system and its data training set without reference to a specific reference molecule.
Resumen de: AU2023276693A1
The present disclosure relates, inter alia, to methods of treating ulcerative colitis with therapeutic intestinal alkaline phosphatases.
Resumen de: CN119780430A
The invention discloses an application of a response marker for treating ulcerative colitis by coprophilous fungi transplantation, and belongs to the technical field of biology, as a further optimization scheme of the invention, the coprophilous fungi comprise Streptococcus, Faecalibacteria, Weissella, Lactococcus and Rombout, and the application of the response marker for treating ulcerative colitis by coprophilous fungi transplantation has the advantages that the application of the response marker for treating ulcerative colitis by coprophilous fungi transplantation is realized, and the application of the response marker for treating ulcerative colitis by coprophilous fungi transplantation is realized. As a further optimization scheme of the invention, the coprophilous bacteria further comprise Streptococcus pluviae, Bifidobacterium longum, Lactococcus garviae, Weissella parasites, Lactococcus fermentum and Lactococcus lactis, and the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae, the Lactococcus pluviae and the In the invention, the flora change before and after coprophilous fungus transplantation treatment is researched on a pati
Resumen de: CN119776531A
The invention relates to application of an SNTB1 gene in occurrence and development of colorectal cancer caused by colitis and proctitis. The key effect of the SNTB1 gene in occurrence and development of colorectal cancer caused by colorectal cancer is creatively disclosed, a new perspective is provided for pathogenesis and molecular fundamental research of colorectal cancer, and development of targeted treatment strategies or prevention methods is facilitated. And secondly, the SNTB1 gene is used as a biomarker, so that effective screening of colitis cancer transformation high-risk groups can be realized, and the early diagnosis rate is improved. Besides, the SNTB1 gene expression promoter provided by the invention can be used for constructing a whole-process animal model for colorectal cancer transformation, and a powerful tool is provided for deeply researching pathogenesis of colorectal cancer and screening drugs. Meanwhile, the prepared preventive pharmaceutical composition is expected to effectively prevent transformation of colitis and proctitis cancers by inhibiting SNTB1 gene expression.
Resumen de: US2025109210A1
The disclosure herein relates to the development and production of novel antibodies and antigen binding fragments thereof that bind TL1A and that are useful in the treatment, prevention and diagnosis of a disease, disorder or inflammation including, for example, autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of final antibody structure being designed de novo by a computer system and its data training set without reference to a specific reference molecule.
Resumen de: US2025109209A1
The disclosure herein relates to the development and production of novel antibodies and antigen binding fragments thereof that bind TL1A and that are useful in the treatment, prevention and diagnosis of a disease, disorder or inflammation including, for example, autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of final antibody structure being designed de novo by a computer system and its data training set without reference to a specific reference molecule.
Resumen de: CN119724354A
The invention discloses a screening method and application of an ulcerative colitis biomarker, EPHX2 can be used as a biomarker for ulcerative colitis detection, provides a new technical means for ulcerative colitis detection, diagnosis, treatment and prognosis evaluation, provides a new direction for research of UC pathogenesis, and provides a new application prospect. And a new possibility is provided for clinical treatment.
Resumen de: WO2025064645A1
The invention relates to diagnostic and therapeutic methods for inflammatory bowel disease (IBD) and to physiologically acceptable compositions of isolated bacterial strains, lysates thereof, and supernatants therefrom for use in treating IBD.
Resumen de: WO2025064813A1
A method for determining a pathological parameter (e.g., a microvilli length (MVL)) of a subject is used to determine a therapeutic response for treatment of the subject. The method includes receiving a pathology image of the subject, identifying a pathological feature and determining a parameter of that feature (e.g., MVL), and determining an aggregate parameter. The pathology image may be pre-processed and/or segmented into regions of interest. The entire pathology image and/or the segmented regions may be subject to feature annotation.
Resumen de: US2025104866A1
A method for determining a pathological parameter (e.g., a microvilli length (MVL)) of a subject is used to determine a therapeutic response for treatment of the subject. The method includes receiving a pathology image of the subject, identifying a pathological feature and determining a parameter of that feature (e.g., MVL), and determining an aggregate parameter. The pathology image may be pre-processed and/or segmented into regions of interest. The entire pathology image and/or the segmented regions may be subject to feature annotation.
Resumen de: CN119255775A
A defecation detection and alert system includes a sensing device mounted to an absorbent article for alerting a caregiver of the presence of solid excreta by analyzing gas expelled from the absorbent article during defecation. The system includes an elongate conduit made of a flexible material and mounted to an absorbent article. The pipeline is connected to a gas sensor arranged in the hanging device, and the gas sensor determines whether defecation occurs in the absorption product or not by detecting existence of hydrogen sulfide gas.
Resumen de: CN119685466A
The invention discloses an application of DUOX2 in identification of ileum subtype and colon subtype Crohn's disease. A group of new DUOX2-epi is analyzed and identified based on single cell transcriptome sequencing, the proportion of the cells in the Crohn disease inflammation tissue is obviously increased, and the proportion of the DUOX2-epi in the colon type Crohn disease inflammation tissue is obviously higher than that in the ileum type Crohn disease inflammation tissue; in addition, in ileum type and colon type Crohn diseases, interaction with surrounding cells is carried out through different mechanisms, so that the occurrence and development of the diseases are promoted. Therefore, based on a DUOX2-epi mediated intercellular communication network, a gene prediction module for predicting different subtypes of Crohn diseases and evaluating the treatment effect of a biological agent is developed, and based on a DUOX2 molecular network, an experimental basis and a research direction are provided for subsequent in-depth research, and a new strategy is expected to be provided for diagnosis and treatment of different subtypes of Crohn diseases.
Resumen de: CN119693421A
The invention discloses a mouse intestinal peristalsis speed detection method and device based on a fluid dense optical flow algorithm, and the method specifically comprises the steps: carrying out the dyeing imaging of a mouse intestinal tract, and shooting a mouse intestinal peristalsis video; carrying out calculation region framing on the complete mouse intestine peristalsis video, extracting an intestine region contour of the mouse, and framing a rectangular image region needing to be calculated; the method comprises the following steps: preprocessing a mouse intestine peristalsis video, filtering breathing frames frame by frame, marking frames influenced by breathing as invalid frames, and skipping in subsequent optical flow calculation; performing optical flow calculation: circularly reading every two frames of the video, and obtaining a group of optical flows after respiration influence is eliminated by using a fluid-based dense optical flow algorithm; and (n-1) groups of optical streams obtained by the n frames of videos are superposed along a time axis to obtain an optical stream index at each pixel point in the whole intestinal region so as to determine the intestinal peristalsis speed of the mouse. The mouse intestinal tract can be monitored in real time and repeatedly evaluated, and theoretical support is provided for diagnosing inflammatory bowel diseases and discovering potential therapeutic drugs.
Resumen de: CN119666500A
The invention provides a biomarker for predicting whether an individual suffers from progression-stage adenoma or not and application of the biomarker. Proteins with significantly different abundance levels in blood of patients and healthy control people at different stages in the colorectal cancer tumor process (inflammatory disease-benign polyp-progression-stage adenoma-colorectal cancer) are analyzed, and a plurality of protein markers capable of being used for progression-stage adenoma risk prediction are screened out. On one hand, a dichotomy algorithm is adopted, a model is built based on a random forest, good performance is shown in distinguishing of progression-stage adenoma and healthy control, the AUC value reaches 0.807, and high diagnostic value is achieved; a six-classification algorithm is further adopted, a model is constructed through gradient lifting, progressive-stage adenoma, early-stage colorectal cancer, benign polyp, inflammatory bowel disease, other cancers and healthy people can be effectively distinguished, the accuracy of the model is 0.78, the consistency is 0.729, the diagnosis sensitivity of the progressive-stage adenoma is 73.4%, and the specificity is 94.7%; and a new way is provided for progression stage adenoma diagnosis.
Resumen de: US2025090497A1
Provided are methods of treatment of a sphingosine 1-phosphate subtype 1 (S1P1) receptor-associated disorder comprising prescribing and/or administering to an individual in need thereof a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopentabindol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
Resumen de: EP4523694A1
The present disclosure relates to: a method, a composition, and a method for producing the same for treating IBD using gastrointestinal contents or excretions modified with an IgA antibody; a method for obtaining an IgA antibody that restores the bacterial flora in the gastrointestinal tract of an IBD patient; a method, a composition, and a method for producing the same for modifying gastrointestinal contents or excretions of an IBD patient using an IgA antibody; and a method, a composition, and a method for producing the same for testing with the diagnostic pharmaceutical drug containing an IgA antibody in a patient treated with the IBD therapeutic agent containing gastrointestinal contents or excretions.
Resumen de: CN119639932A
The invention discloses an application of intestinal bacteria in an ulcerative colitis prediction technology, and belongs to the technical field of biology, and the intestinal bacteria are Alistipes finegoldii; the method comprises the following steps: detecting the relative abundance of Alistipes finegii in an excrement sample of a patient, and using the low relative abundance of Alistipes finegii to predict the disease activity of ulcerative colitis; according to the application disclosed by the invention, not only is the association between the Alistipes finegili and the UC disease activity verified, but also the potential action mechanism of the Alistipes finegili is further explored. By means of 16s amplicon sequencing and transcriptomics combined analysis, it is found that the Alistipes finegili plays an anti-inflammatory role through an Hsp90/AMPK/ACC signal channel, and the intestinal barrier function is maintained. The invention verifies that a new view angle is provided for the effect of the Alistipes finegili in the UC pathogenesis, and provides a theoretical basis for developing a treatment strategy based on the strain.
Resumen de: CN119619519A
The invention relates to application of a C7orf10 protein level detection agent in preparation of a mitochondrial disease diagnostic agent. Research finds that C7orf10 protein level rise is shown in cells with mitochondrial dysfunction caused by different gene defects and in the body of a patient, which indicates that the C7orf10 protein level rise can be used as a molecular marker of the mitochondrial dysfunction, so that a C7orf10 protein level detection agent can be used as a mitochondrial disease diagnosis agent, and the clinical application prospect is wide. Therefore, a novel diagnosis method and a novel diagnosis reagent are provided for diagnosis of mitochondrial diseases.
Resumen de: CN119613546A
The invention discloses an IL-10 antibody and an application thereof. The anti-human IL-10 monoclonal antibody human IL-10 protein provided by the invention has relatively strong affinity, can be used for detecting the expression of the human IL-10 protein, can also be applied to immunotherapy independently or in combination with other methods, and has diagnosis and treatment values in tumors, inflammatory bowel diseases and rheumatism immune diseases.
Resumen de: US2025084174A1
The invention relates to binding molecules, such as antibodies, that bind to the chemokine receptor CCR9. More particularly, the invention relates to the treatment of CCR9-mediated diseases or conditions such as inflammatory bowel disease (IBD), and methods for the detection of CCR9, which make use of the binding molecules of the invention.
Resumen de: US2025084480A1
Disclosed are methods for treating active eosinophilic colitis (EoC), or in certain aspects, inflammatory bowel disease (IBD), in an individual in need thereof. In one aspect, the methods may comprise a) assaying a tissue sample obtained from a colon of an individual who may be in need of such treatment, wherein the assaying comprises detecting expression of one or more gene of a transcriptome gene set; b) calculating a score based on the expression of one or more gene of a transcriptome gene set; and c) selecting a tissue sample that exhibits a score indicative of EoC or IBD. The methods may further comprise administering an EoC or IBD therapy to the individual whose tissue sample exhibited a score indicative of having EoC or IBD.
Resumen de: AU2023327783A1
Embodiments include a method for detecting small intestinal bacterial overgrowth, SIBO, the method comprising: obtaining data representing a time series of readings from gas sensor hardware housed within an ingestible capsule device orally ingested by a subject, identifying the data corresponding to timing of passage through the small intestine, and determining whether or not the data indicates presence of SIBO.
Resumen de: CN119587515A
The invention belongs to the field of biological medicines, and particularly relates to application of nordihydroguaiamic acid and derivatives thereof in preparation of products for treating inflammatory bowel diseases. By exogenous supplementation of nordihydroguaiamic acid (NDGA), DSS-induced mouse enteritis is remarkably relieved, survival prognosis of mice is improved, mucosal barrier dysfunction of UC mice is remarkably improved, the number of inflammatory macrophage subgroups is reduced, transcription generation of colon tissue proinflammatory factors and activated cleavage of pyroptosis-related proteins are inhibited, and the application of the NDGA is developed. Good anti-inflammatory effect and intestinal protection effect are achieved. The NDGA is further found to be capable of remarkably improving the mucosal barrier function disorder of the UC mouse, and the NDGA is prompted to have a good intestinal protection effect; the NDGA can inhibit the transcriptional generation of IL-1beta by regulating and controlling the NR4A1-Serpin1 pathway and reduce the co-localization of NR4A1 and NLRP3 in macrophages, which prompts that the NDGA can regulate and control the interaction relationship of NR4A1 and NLRP3 to inhibit inflammation.
Nº publicación: CN119591712A 11/03/2025
Solicitante:
NIUMAI BIOTECHNOLOGY SUZHOU CO LTD
\u7EBD\u8FC8\u751F\u7269\u79D1\u6280\uFF08\u82CF\u5DDE\uFF09\u6709\u9650\u516C\u53F8
Resumen de: CN119591712A
A fully humanized mouse is immunized by using a BDCA-2 extracellular domain (ECD) antigen, positive clones are screened out through a hybridoma technology, and the specific monoclonal antibody targeting human plasma cell-like dendritic cells is obtained through gene sequencing and recombinant expression purification. The antibody disclosed by the invention has high binding capacity to human BDCA-2, and can be used for developing drugs or diagnostic reagents for treating or preventing inflammatory diseases or autoimmune diseases.
BOPI
Sede Electrónica
